These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 16942629)
21. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830 [TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Nevitt SJ; Jones AP; Howard J Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137 [TBL] [Abstract][Full Text] [Related]
23. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia. Ballas SK; Connes P; Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261 [TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective. Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390 [TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia. Keikhaei B; Yousefi H; Bahadoram M Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428 [TBL] [Abstract][Full Text] [Related]
28. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341 [TBL] [Abstract][Full Text] [Related]
29. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers. Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480 [TBL] [Abstract][Full Text] [Related]
30. Magnesium for treating sickle cell disease. Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421 [TBL] [Abstract][Full Text] [Related]
31. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375 [TBL] [Abstract][Full Text] [Related]
32. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Saleh AW; Hillen HF; Duits AJ Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885 [TBL] [Abstract][Full Text] [Related]
33. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
34. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591 [TBL] [Abstract][Full Text] [Related]
35. Use of hydroxyurea in children with sickle cell disease: what comes next? Ohene-Frempong K; Smith-Whitley K Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199 [TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Sumoza A; de Bisotti R; Sumoza D; Fairbanks V Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569 [TBL] [Abstract][Full Text] [Related]
37. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin. el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719 [TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea for the treatment of sickle cell disease. Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478 [TBL] [Abstract][Full Text] [Related]
39. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377 [TBL] [Abstract][Full Text] [Related]
40. Interventions for chronic kidney disease in people with sickle cell disease. Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]